Eli Lilly's Mounjaro drug not subsidised for 450,000 Australians

Eli Lilly has declined a recommendation for the Australian government to subsidise its weight loss drug Mounjaro, impacting approximately 450,000 Australians with Type 2 diabetes. The decision means these individuals will miss out on financial assistance for the medication, which is considered 'unviable' for subsidy.

Read the full story at Sydney Morning Herald→